| 37.33 -0.47 (-1.24%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 52.71 |
1-year : | 58.58 |
| Resists | First : | 45.13 |
Second : | 50.15 |
| Pivot price | 43.48 |
|||
| Supports | First : | 37 |
Second : | 30.79 |
| MAs | MA(5) : | 40 |
MA(20) : | 44.57 |
| MA(100) : | 36.88  |
MA(250) : | 27.63 |
|
| MACD | MACD : | -1.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 2.5 |
D(3) : | 7.6 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 50.15 | Low : | 13.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LBRX ] has closed above bottom band by 6.8%. Bollinger Bands are 97.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.63 - 38.9 | 38.9 - 39.1 |
| Low: | 36.32 - 36.68 | 36.68 - 36.95 |
| Close: | 36.83 - 37.32 | 37.32 - 37.69 |
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Mon, 14 Sep 2026
LB Pharmaceuticals (LBRX) CFO reports zero share ownership - Stock Titan
Mon, 10 Aug 2026
LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) Stock Price, News & Analysis - kalkine.ca
Wed, 29 Jul 2026
LB Pharmaceuticals Plans $150M Raise for LB-102 Expansion - Stock Titan
Wed, 29 Jul 2026
LB Pharmaceuticals raises $150M in private placement - Investing.com
Wed, 29 Jul 2026
LB Pharmaceuticals Announces $150 Million Private Placement - GlobeNewswire
Fri, 12 Sep 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering - Mintz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 101.4 (%) |
| Shares Short | 5,160 (K) |
| Shares Short P.Month | 4,260 (K) |
| EPS | -5.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30 % |
| Return on Equity (ttm) | -50 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -7.32 |
| PEG Ratio | 0 |
| Price to Book value | 3.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|